Chauhan, Dharminder

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 804

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell

Multiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways

Cited by 694

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood

Multiple Myeloma Research and TreatmentsCell death mechanisms and regulation

Cited by 669

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell

Ubiquitin and proteasome pathwaysMultiple Myeloma Research and Treatments

Cited by 589

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T., & Anderson, K. (1996) · Blood

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 563

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene

Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer

Cited by 478

Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells

Hideshima, T., Ikeda, H., Chauhan, D., Okawa, Y., Raje, N., Podar, K., Mitsiades, C., Munshi, N. C., Richardson, P. G., Carrasco, R. D., et al. (2009) · Blood

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 363

Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7.

Lamberto, I., Liu, X., Seo, H.-S., Schauer, N. J., Iacob, R. E., Hu, W., Das, D., Mikhailova, T., Weisberg, E. L., Engen, J. R., et al. (2017) · Cell Chemical Biology

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 192

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

Hideshima, T., Chauhan, D., Hayashi, T., Akiyama, M., Mitsiades, N., Mitsiades, C., Podar, K., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2003) · Oncogene

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 164

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.

Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., et al. (2020) · Scientific Reports

Ubiquitin and proteasome pathwaysCancer-related Molecular Pathways

Cited by 125

Transforming Growth Factor β Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment

Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsTGF-β signaling in diseases

Cited by 110

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Perrone, G., Hideshima, T., Ikeda, H., Okawa, Y., Calabrese, E., Gorgun, G., Santo, L., Cirstea, D., Raje, N., Chauhan, D., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsVitamin C and Antioxidants Research

Cited by 109

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 109

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells

Tian, Z., Zhao, J.-J., Tai, Y.-T., Amin, S. B., Hu, Y., Berger, A. J., Richardson, P., Chauhan, D., & Anderson, K. C. (2012) · Blood

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 82

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD®immunomodulatory drug pomalidomide

Das, D. S., Ray, A., Song, Y., Richardson, P., Trikha, M., Chauhan, D., & Anderson, K. C. (2015) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 49

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status

Cea, M., Cagnetta, A., Acharya, C., Acharya, P., Tai, Y.-T., Yang, C., Lovera, D., Soncini, D., Miglino, M., Fraternali-Orcioni, G., et al. (2016) · Clinical Cancer Research

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 28